Monopar Therapeutics Inc. 1IY.F Stock
Monopar Therapeutics Inc. Price Chart
Monopar Therapeutics Inc. 1IY.F Financial and Trading Overview
| Monopar Therapeutics Inc. stock price | 0.55 EUR |
| Previous Close | 0.78 EUR |
| Open | 0.78 EUR |
| Bid | 0 EUR x N/A |
| Ask | 0 EUR x N/A |
| Day's Range | 0.76 - 0.76 EUR |
| 52 Week Range | 0.76 - 4.64 EUR |
| Volume | 250 EUR |
| Avg. Volume | 57 EUR |
| Market Cap | 10.05M EUR |
| Beta (5Y Monthly) | 0.994548 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.49 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.67 EUR |
1IY.F Valuation Measures
| Enterprise Value | -1429137 EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.5135135 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.1242603 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Monopar Therapeutics Inc. Stock Price History
| Beta (5Y Monthly) | 0.994548 |
| 52-Week Change | -56.21% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.64 EUR |
| 52 Week Low | 0.76 EUR |
| 50-Day Moving Average | 1.02 EUR |
| 200-Day Moving Average | 2.05 EUR |
1IY.F Share Statistics
| Avg. Volume (3 month) | 57 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 13.22M |
| Float | 4.23M |
| Short Ratio | N/A |
| % Held by Insiders | 62.59% |
| % Held by Institutions | 1.42% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -44.33% |
| Return on Equity (ttm) | -80.99% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -10493472 EUR |
| Diluted EPS (ttm) | -0.72 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.68M EUR |
| Total Cash Per Share (mrq) | 0.88 EUR |
| Total Debt (mrq) | 0 EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 4.08 |
| Book Value Per Share (mrq) | 0.676 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7032172 EUR |
| Levered Free Cash Flow (ttm) | -3109842 EUR |
Profile of Monopar Therapeutics Inc.
| Country | Germany |
| State | IL |
| City | Wilmette |
| Address | 1000 Skokie Boulevard |
| ZIP | 60091 |
| Phone | 847 388 0349 |
| Website | https://www.monopartx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 11 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Q&A For Monopar Therapeutics Inc. Stock
What is a current 1IY.F stock price?
Monopar Therapeutics Inc. 1IY.F stock price today per share is 0.55 EUR.
How to purchase Monopar Therapeutics Inc. stock?
You can buy 1IY.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Monopar Therapeutics Inc.?
The stock symbol or ticker of Monopar Therapeutics Inc. is 1IY.F.
Which industry does the Monopar Therapeutics Inc. company belong to?
The Monopar Therapeutics Inc. industry is Biotechnology.
How many shares does Monopar Therapeutics Inc. have in circulation?
The max supply of Monopar Therapeutics Inc. shares is 25.55M.
What is Monopar Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Monopar Therapeutics Inc. PE Ratio is now.
What was Monopar Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Monopar Therapeutics Inc. EPS is -0.49 EUR over the trailing 12 months.
Which sector does the Monopar Therapeutics Inc. company belong to?
The Monopar Therapeutics Inc. sector is Healthcare.